DexCom, Inc. $DXCM Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 96.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,025 shares of the medical device company’s stock after selling 948,754 shares during the quarter. Pacer Advisors Inc.’s holdings in DexCom were worth $2,137,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom during the first quarter worth $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom during the fourth quarter worth $32,000. Wellington Grp LLC lifted its holdings in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new stake in shares of DexCom during the fourth quarter valued at $36,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Mizuho lifted their price target on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price for the company. Bank of America dropped their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.71.

Insider Activity at DexCom

In related news, EVP Jon Coleman sold 4,912 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president directly owned 100,361 shares in the company, valued at approximately $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 102,506 shares of company stock worth $7,535,898 in the last 90 days. 0.28% of the stock is owned by corporate insiders.

DexCom Trading Up 2.1%

Shares of NASDAQ DXCM opened at $84.75 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.85. The business has a 50-day moving average price of $74.42 and a two-hundred day moving average price of $69.73. The firm has a market capitalization of $31.98 billion, a PE ratio of 33.50, a PEG ratio of 1.39 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.65 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.